Acrivon Therapeutics (ACRV) Total Current Liabilities (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Total Current Liabilities of $11.1 million for Q1 2026, down 18.42% year-over-year from $13.6 million in Q1 2025, and down 29.43% quarter-over-quarter from $15.7 million in Q4 2025.
Acrivon Therapeutics (ACRV) Total Current Liabilities (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Total Current Liabilities for 6 consecutive years, with $11.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 18.42% year-over-year to $11.1 million; the TTM figure through Mar 2026 stood at $11.1 million (down 18.42% YoY), while the FY2025 annual figure was $15.7 million, down 9.0% from the prior year.
- Total Current Liabilities retreated to $11.1 million in Q1 2026 per ACRV's latest filing, from $15.7 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $17.2 million in Q4 2024 and bottomed at $5.7 million in Q1 2023.
- Historically, Total Current Liabilities has averaged $11.3 million across 5 years, with a median of $11.3 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 123.61% — and 2026, when it slipped 18.42%.
- Acrivon Therapeutics' Total Current Liabilities stood at $6.5 million in 2022, then soared by 104.16% to $13.3 million in 2023, then rose by 29.4% to $17.2 million in 2024, then decreased by 9.0% to $15.7 million in 2025, then dropped by 29.43% to $11.1 million in 2026.
- Business Quant data shows ACRV's Total Current Liabilities at $11.1 million in Q1 2026, $15.7 million in Q4 2025, and $14.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Acrivon Therapeutics | 92.26 Mn | 92.26 Mn | - | 11.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.45 Mn |
| Mar 31, 2026 | 11.05 Mn |
| Dec 31, 2025 | 15.66 Mn |
| Sep 30, 2025 | 14.89 Mn |
| Jun 30, 2025 | 13.43 Mn |
| Mar 31, 2025 | 13.55 Mn |
| Dec 31, 2024 | 17.21 Mn |
| Sep 30, 2024 | 14.82 Mn |
| Jun 30, 2024 | 11.28 Mn |
| Mar 31, 2024 | 9.04 Mn |
| Dec 31, 2023 | 13.30 Mn |
| Sep 30, 2023 | 9.30 Mn |
| Jun 30, 2023 | 7.02 Mn |
| Mar 31, 2023 | 5.68 Mn |
| Dec 31, 2022 | 6.52 Mn |
| Sep 30, 2022 | 6.39 Mn |
| Dec 31, 2021 | 2.91 Mn |